Table 4 Variant classification scheme.

From: A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma

Pattern

Level

Evidence

Sensitivity to targeted drugs

1A

Drug is FDA-approved for lung cancers harbouring the variant.

1B

Drug is clinically effective in the biomarker-selected cohort of lung cancer. The variant, which has a definite function feature, belongs to the cohort.

2A

Drug is FDA-approved for another tumour type harbouring the variant. Clinical trials have proved its effectiveness in lung cancer patients with the variant.

2B

Drug is FDA-approved for another tumour type harbouring the variant. Case reports have indicated its effectiveness in lung cancer patients with the variant.

2C

Drug is FDA-approved for another tumour type harbouring the variant. Pre-clinical research has indicated its effectiveness in lung cancer patients with the variant.

Resistance to targeted drugs

1A

NCCN guideline has clearly indicated that the variant is associated with resistance to the FDA-approved lung cancer drug.

1B

NCCN guideline has indicated drug resistance to the biomarker-selected cohort of lung cancer. The variant, which has a definite function feature, belongs to the cohort.

2A

Case reports have indicated drug resistance in the lung cancer patients with the variant.

2B

Pre-clinical research has indicated drug resistance in lung cancer patients with the variant.

Back to article page